[{"data":1,"prerenderedAt":137},["ShallowReactive",2],{"drug-palivizumab":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":34,"contraindications":67,"warnings":77,"renal":85,"monitoring":86,"interactions":87,"review":88,"examples":91,"atc":99,"iran":101,"links":113,"populations":127},"palivizumab",1,{"fa":7,"en":8},"پالیویزوماب","Palivizumab","anti-infectives",{"fa":11,"en":12},"آنتی‌بادی مونوکلونال ضد RSV","Anti-RSV monoclonal antibody",[14],{"name":15,"market":16},"Synagis","UK",[18,19,7],"synagis","سیناژیس",[21],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":29,"refs":30},"vial-100","injection","im","100 mg\u002FmL (50 mg\u002F0.5 mL or 100 mg\u002F1 mL vial)",{"amount":27,"unit":28,"perVolumeMl":5},100,"mg",[16],[31],{"source":32,"section":33},"emc-synagis","6.5",[35],{"id":36,"disease":37,"label":38,"population":41,"type":45,"unit":28,"dose":46,"refs":49,"durationDays":52,"notes":53},"rsv","rsv-prophylaxis",{"fa":39,"en":40},"پیشگیری RSV در کودک پرخطر — ۱۵ mg\u002Fkg عضلانی ماهی یک بار در فصل RSV","RSV prophylaxis in high-risk children — 15 mg\u002Fkg IM once a MONTH during the RSV season",{"maxAge":42},{"value":43,"unit":44},2,"year","weightBased",{"perKgPerDose":47,"intervalHours":48},15,24,[50],{"source":32,"section":51},"4.2",{"min":5,"max":5},[54,60],{"text":55,"refs":58},{"fa":56,"en":57},"یک دوز در هر ماه (نه روزانه) در طول فصل RSV؛ اولین دوز ترجیحاً پیش از شروع فصل؛ اغلب ۵ دوز در فصل. حجم (mL) = وزن × ۰٫۱۵.","One dose each MONTH (not daily) through the RSV season; first dose preferably before the season starts; most experience is with 5 doses per season. Volume (mL) = weight × 0.15.",[59],{"source":32,"section":51},{"text":61,"refs":64},{"fa":62,"en":63},"اندیکاسیون: نوزاد ≤۳۵ هفته و زیر ۶ ماه در شروع فصل؛ زیر ۲ سال با دیسپلازی برونکوپولمونری درمان‌شده در ۶ ماه اخیر؛ زیر ۲ سال با بیماری مادرزادی قلبی مهم.","Indications: born ≤35 weeks and \u003C6 months at season onset; \u003C2 y treated for bronchopulmonary dysplasia in the last 6 months; \u003C2 y with haemodynamically significant congenital heart disease.",[65],{"source":32,"section":66},"4.1",[68],{"id":69,"severity":70,"text":71,"refs":74},"hyper","block",{"fa":72,"en":73},"حساسیت به پالیویزوماب، اجزا یا سایر آنتی‌بادی‌های مونوکلونال انسانی‌شده.","Hypersensitivity to palivizumab, excipients or other humanised monoclonal antibodies.",[75],{"source":32,"section":76},"4.3",[78],{"text":79,"refs":82},{"fa":80,"en":81},"آنافیلاکسی (گاه کشنده) — داروی درمان آن در دسترس باشد.","Anaphylaxis (sometimes fatal) — have treatment available.",[83],{"source":32,"section":84},"4.4",[],[],[],{"status":89,"reviewer":90,"date":90},"unverified",null,[92],{"regimen":36,"formulation":22,"input":93,"expect":96},{"ageMonths":94,"weightKg":95},4,5,{"perDose":97,"mlPerDose":98},75,0.75,[100],"J06BD01",{"status":102,"forms":103,"refs":108},"registered",[104],{"code":105,"en":106,"fa":107},"19965","PALIVIZUMAB 50MG VIAL","ویال پالیویزومب ۵۰ میلی‌گرم",[109],{"source":110,"section":111,"url":112},"darooyab-generic","G-3506\u002FPalivizumab","https:\u002F\u002Fwww.darooyab.ir\u002FG-3506\u002FPalivizumab",[114,118,121,123],{"kind":115,"url":116,"label":117},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa698034.html","Palivizumab Injection",{"kind":119,"url":120,"label":100},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=J06BD01",{"kind":122,"url":112,"label":8},"darooyab",{"kind":124,"url":125,"label":126},"emc","https:\u002F\u002Fwww.medicines.org.uk\u002Femc\u002Fproduct\u002F6963\u002Fsmpc","eMC Synagis",{"pregnancy":128},{"level":129,"quote":130,"text":131,"refs":134},"caution","مصرف در بارداری پالیویزوماب گروه C در شرايط خاص و نظارت ويژه پزشك قابل استفاده است:",{"fa":132,"en":133},"دارویاب: گروه C — فقط اگر فایده بیشتر از خطر باشد.","Darooyab: category C — only if benefit outweighs risk.",[135],{"source":110,"section":136,"url":112},"G-3506\u002FPalivizumab — مصرف در بارداری",1792156190448]